Allergen labeling strategy
This article was originally published in The Tan Sheet
Executive Summary
FDA announces a Sept. 16 public hearing for collecting comments on the agency's "long-term strategy to assist manufacturers in using allergen advisory labeling that is truthful and not misleading, conveys a clear and uniform message, and adequately informs food-allergic consumers and their caregivers," according to an Aug. 8 Federal Register notice. In November 2006, FDA published a final guidance for industry on food allergens and the Food Allergen Labeling and Consumer Protection Act of 2004, but has not decided if it will develop guidance for using advisory labeling (1"The Tan Sheet" Nov. 6, 2006, In Brief)...
You may also be interested in...
FALCPA Q&A
FDA publishes a final guidance for industry on food allergens and the Food Allergen Labeling & Consumer Protection Act of 2004 (FALCPA). The fourth edition of the guidance published in October answers old and new industry questions about allergens and FALCPA. Recently added portions include an extended list of tree nuts and a more thorough definition of wheat. FDA's previous guidance on food allergens and FALCPA was issued April 6...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.